Now showing items 1-3 of 3

    • 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. 

      Peck, B; Bland, P; Mavrommati, I; Muirhead, G; Cottom, H; Wai, PT; Maguire, SL; Barker, HE; Morrison, E; Kriplani, D; Yu, L; Gibson, A; Falgari, G; Brennan, K; Farnie, G; Buus, R; Marlow, R; Novo, D; Knight, E; Guppy, N; Kolarevic, D; Susnjar, S; Milijic, NM; Naidoo, K; Gazinska, P; Roxanis, I; Pancholi, S; Martin, L-A; Holgersen, EM; Cheang, MCU; Noor, F; Postel-Vinay, S; Quinn, G; McDade, S; Krasny, L; Huang, P; Daley, F; Wallberg, F; Choudhary, JS; Haider, S; Tutt, AN; Natrajan, R (2021-01-28)
      Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies ...
    • Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. 

      Natrajan, R; Wilkerson, PM; Marchiò, C; Piscuoglio, S; Ng, CKY; Wai, P; Lambros, MB; Samartzis, EP; Dedes, KJ; Frankum, J; Bajrami, I; Kopec, A; Mackay, A; A'hern, R; Fenwick, K; Kozarewa, I; Hakas, J; Mitsopoulos, C; Hardisson, D; Lord, CJ; Kumar-Sinha, C; Ashworth, A; Weigelt, B; Sapino, A; Chinnaiyan, AM; Maher, CA; Reis-Filho, JS (2014-04)
      Micropapillary carcinoma (MPC) is a rare histological special type of breast cancer, characterized by an aggressive clinical behaviour and a pattern of copy number aberrations (CNAs) distinct from that of grade- and oestrogen ...
    • Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. 

      Yap, TA; O'Carrigan, B; Penney, MS; Lim, JS; Brown, JS; de Miguel Luken, MJ; Tunariu, N; Perez-Lopez, R; Rodrigues, DN; Riisnaes, R; Figueiredo, I; Carreira, S; Hare, B; McDermott, K; Khalique, S; Williamson, CT; Natrajan, R; Pettitt, SJ; Lord, CJ; Banerji, U; Pollard, J; Lopez, J; de Bono, JS (2020-09)
      <h4>Purpose</h4>Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with ...